Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 165 articles:
HTML format



Single Articles


    March 2024
  1. MORI K, Hatakeyama S, Enokida H, Miyake H, et al
    Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
    Int J Urol. 2024;31:194-207.
    PubMed     Abstract available


  2. ISHIKAWA Y, Tanaka H, Fujiwara M, Nakamura Y, et al
    Incidence and predictors of intraoperative hypotension during transurethral bladder tumor resection with oral 5-aminolevulinic acid.
    Int J Urol. 2024;31:238-244.
    PubMed     Abstract available


  3. MATSUKAWA A, Morizane S, Shimizu R, Teraoka S, et al
    Chronic kidney disease and Charlson comorbidity index predict complications after robot-assisted radical cystectomy: A single-center study in Japan.
    Int J Urol. 2024;31:231-237.
    PubMed     Abstract available


    February 2024
  4. KONDO T
    Editorial Comment to Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
    Int J Urol. 2024;31:133.
    PubMed    


  5. SUHARA Y, Urabe F, Yoshihara K, Kurawaki S, et al
    Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
    Int J Urol. 2024;31:125-132.
    PubMed     Abstract available


    January 2024
  6. UKIMURA O
    Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
    PubMed    


  7. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
    Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
    PubMed     Abstract available


  8. NAGAKAWA S, Shiota M, Takamatsu D, Tsukahara S, et al
    Clinical features and oncological outcomes of bladder cancer microsatellite instability.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15370.
    PubMed     Abstract available


  9. NAKAMOTO T, Yoshida T
    Response to Comment: Future goals of upper tract urothelial carcinoma endoscopic management.
    Int J Urol. 2024;31:90.
    PubMed    


  10. MORI K, Yanagisawa T, Fukuokaya W, Iwatani K, et al
    Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
    Int J Urol. 2024;31:25-31.
    PubMed     Abstract available


  11. KIKUCHI E, Ng CF, Kitamura H, Ku JH, et al
    Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific.
    Int J Urol. 2024;31:32-38.
    PubMed     Abstract available


  12. JUE JS, Alameddine M, Armenakas NA
    Future goals of upper tract urothelial carcinoma endoscopic management.
    Int J Urol. 2024;31:89.
    PubMed    


    December 2023
  13. GOTO Y
    Editorial Comment on Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15360.
    PubMed    


  14. ARAI S
    Editorial Comment on Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15361.
    PubMed    


  15. HASHIMOTO T
    Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1186-1187.
    PubMed    


  16. TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
    Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1180-1186.
    PubMed     Abstract available


  17. KATO M, Uchida J
    Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
    Int J Urol. 2023;30:1068-1077.
    PubMed     Abstract available


    November 2023
  18. TOMIYAMA E, Fujita K, Hashimoto M, Uemura H, et al
    Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15338.
    PubMed     Abstract available


  19. ROSAZZA M, Soria F, Gontero P
    Editorial comment-Risk stratification and management of nonmuscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15340.
    PubMed    


  20. NUNES FM, Apolonio JD, Mota-Pinto A, Leao R, et al
    Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Nov 14. doi: 10.1111/iju.15335.
    PubMed     Abstract available


  21. MORI K
    Editorial Comment from Dr. Mori to texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1059.
    PubMed    


  22. CHEN W, Yokoyama M, Waseda Y, Kobayashi M, et al
    Surgical outcomes of robot-assisted radical cystectomy in octogenarian or older patients: A Japanese nationwide study.
    Int J Urol. 2023;30:1014-1019.
    PubMed     Abstract available


  23. KANEKO H, Fujiwara M, Tanaka H, Kimura K, et al
    Texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1056-1058.
    PubMed    


    October 2023
  24. KU JH, Lee LS, Lin TP, Kikuchi E, et al
    Risk stratification and management of non-muscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Oct 6. doi: 10.1111/iju.15309.
    PubMed     Abstract available


  25. SHIGETA K
    Editorial Comments to "Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort".
    Int J Urol. 2023;30:859.
    PubMed    


  26. TABATA H, Tanaka T, Shindo T, Hashimoto K, et al
    Urethrectomy via parapenile incision to complete robot-assisted radical cystectomy in a spine position for male patients.
    Int J Urol. 2023;30:936-938.
    PubMed    


  27. SOMIYA S, Kobori G, Ito K, Nakagawa H, et al
    Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort.
    Int J Urol. 2023;30:853-858.
    PubMed     Abstract available


    September 2023
  28. KIKUCHI E, Hayakawa N
    Editorial Comment to "Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study".
    Int J Urol. 2023 Sep 27. doi: 10.1111/iju.15311.
    PubMed    


  29. FUKUSHIMA H
    Editorial Comment to Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Int J Urol. 2023 Sep 22. doi: 10.1111/iju.15308.
    PubMed    


  30. SZARVAS T
    Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
    Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15296.
    PubMed    


  31. SATO T, Sano T, Kawamura S, Ikeda Y, et al
    Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study.
    Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15294.
    PubMed     Abstract available


  32. KIKUCHI E, Hayakawa N
    Editorial Comment to "The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion".
    Int J Urol. 2023;30:786-787.
    PubMed    


  33. HARA T, Furukawa J, Okamura Y, Bando Y, et al
    The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.
    Int J Urol. 2023;30:779-786.
    PubMed     Abstract available


  34. TOMISAKI I, Harada M, Sakano S, Terado M, et al
    Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
    Int J Urol. 2023;30:738-745.
    PubMed     Abstract available


  35. ITO K, Kita Y, Kobayashi T
    Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Int J Urol. 2023;30:696-703.
    PubMed     Abstract available


  36. GOTO Y
    Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Int J Urol. 2023;30:704.
    PubMed    


    August 2023
  37. GOTO Y
    Editorial Comment to Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15286.
    PubMed    


  38. NISHIMURA N, Miyake M, Nakahama T, Miyamoto T, et al
    Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15283.
    PubMed     Abstract available


  39. LIANG HQ, Liao NK, Yang SB, Wei QJ, et al
    Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
    Int J Urol. 2023 Aug 21. doi: 10.1111/iju.15276.
    PubMed     Abstract available


  40. GOTO Y
    Editorial Comment to Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:647-648.
    PubMed    


  41. YOSHIDA T, Ohe C, Nakamoto T, Kinoshita H, et al
    Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:634-647.
    PubMed     Abstract available


  42. KONDO T
    Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:657.
    PubMed    


  43. SAZUKA T
    Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:658.
    PubMed    


  44. OKUYAMA Y, Hatakeyama S, Tabata R, Fujimori D, et al
    Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:649-657.
    PubMed     Abstract available


    July 2023
  45. MIYAKE M, Nishimura N, Fujii T, Fujimoto K, et al
    Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Int J Urol. 2023 Jul 31. doi: 10.1111/iju.15263.
    PubMed     Abstract available


  46. HAGIMOTO H, Kambe T, Mine Y, Kokubun H, et al
    Necessity of prophylactic drainage tube in retroperitoneal laparoscopic nephroureterectomy with open distal ureterectomy: A matched-pair analysis.
    Int J Urol. 2023;30:579-584.
    PubMed     Abstract available


  47. ISHII N, Hatakeyama S, Miura H, Tanaka R, et al
    Trends in the age of hospitalized patients with urological cancers: A 17-year experience.
    Int J Urol. 2023;30:572-578.
    PubMed     Abstract available


    May 2023
  48. LIU Z, Leow JJ, Yong DZP
    Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2023 May 10. doi: 10.1111/iju.15200.
    PubMed    


  49. CHOO ZW, Leow JJ, Vong E, Chia PL, et al
    Editorial Comment to Impact of the coronavirus disease-2019 pandemic on the number of patients undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospect
    Int J Urol. 2023;30:471-472.
    PubMed    


  50. TSURUTA K, Majima T, Nishikimi T, Kashima A, et al
    Impact of the coronavirus disease 2019 pandemic on the number of undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospective study.
    Int J Urol. 2023;30:464-471.
    PubMed     Abstract available


    April 2023
  51. MASTROIANNI R, Torregiani G, Simone G
    Editorial Comment on Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
    Int J Urol. 2023;30:373-374.
    PubMed    


  52. TAFURI A, Panunzio A, Gozzo A, Ornaghi PI, et al
    Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
    Int J Urol. 2023;30:366-373.
    PubMed     Abstract available


    March 2023
  53. MATSUMOTO K
    Editorial Comment on Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.
    Int J Urol. 2023 Mar 16. doi: 10.1111/iju.15177.
    PubMed    


  54. MOEEN AM
    Editorial Comment on Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter-related bladder discomfort in TURBT: A randomized, double-blind, controlled trial.
    Int J Urol. 2023;30:270-271.
    PubMed    


  55. CHEN W, Yokoyama M, Kobayashi M, Fan B, et al
    Trends of radical cystectomy and comparisons of surgical outcomes among surgical approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide database study.
    Int J Urol. 2023;30:258-263.
    PubMed     Abstract available


  56. MIYAKE M, Oda Y, Nishimura N, Shimizu T, et al
    Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and C3H mice.
    Int J Urol. 2023;30:328-330.
    PubMed    


  57. SINGH A, Kayina CA, Naik N, Ganesh V, et al
    Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter related bladder discomfort in transurethral resection of bladder tumors: A randomized, double blind, controlled trial.
    Int J Urol. 2023;30:264-270.
    PubMed     Abstract available


    February 2023
  58. MIYAMOTO T, Miyake M, Nakahama T, Nishimura N, et al
    Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.
    Int J Urol. 2023 Feb 14. doi: 10.1111/iju.15162.
    PubMed     Abstract available


  59. YANG H, Zhang Z, Zhao K, Zhang Y, et al
    Initial experience with 161 extraperitoneal laparoscopic radical cystectomy procedures: Comparison with transabdominal laparoscopic radical cystectomy.
    Int J Urol. 2023;30:155-160.
    PubMed     Abstract available


    January 2023
  60. NASELLI A, Pirola GM
    Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2023 Jan 18. doi: 10.1111/iju.15150.
    PubMed    


  61. KATAYAMA S, Pradere B, Grossman NC, Potretzke AM, et al
    Biological and prognostic implications of biopsy upgrading for high-grade upper tract urothelial carcinoma at nephroureterectomy.
    Int J Urol. 2023;30:63-69.
    PubMed     Abstract available


    December 2022
  62. NAKAMURA Y, Fukushima H, Yoshitomi K, Soma T, et al
    Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Dec 27. doi: 10.1111/iju.15136.
    PubMed     Abstract available


  63. TAGUCHI S, Kawai T, Nakagawa T, Miyakawa J, et al
    Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020).
    Int J Urol. 2022;29:1462-1469.
    PubMed     Abstract available


    November 2022
  64. NISHIKAWA R, Miyake M, Morizane S, Shimizu R, et al
    C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guerin therapy: A Japan Urological Oncology Group study analysis.
    Int J Urol. 2022 Nov 30. doi: 10.1111/iju.15106.
    PubMed     Abstract available


  65. YAMAMOTO A, Kawashima A, Uemura T, Yamamichi G, et al
    Anticancer maintenance chemotherapy prolonged prognosis of metastatic urothelial carcinoma patients: A single institute retrospective study using propensity score matching.
    Int J Urol. 2022;29:1294-1303.
    PubMed     Abstract available


    September 2022
  66. LEOW JJ, Chen K, Yuen JSP
    Editorial Comment to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle invasive bladder cancer.
    Int J Urol. 2022 Sep 12. doi: 10.1111/iju.15037.
    PubMed    


    July 2022
  67. IDE H
    Editorial Comment from Dr Ide to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14988.
    PubMed    


  68. NASELLI A, Pirola GM
    Editorial Comment from Dr Naselli and Dr Pirola to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.15000.
    PubMed    


  69. TOCHIGI K, Nagayama J, Bando S, Ishiyama A, et al
    Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14974.
    PubMed     Abstract available


  70. MURAKAMI Y, Matsumoto K, Miyake M, Amano N, et al
    Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14976.
    PubMed     Abstract available


  71. ISHIYAMA Y
    Editorial Comment to Impact of early postoperative creatinine increase on mid-term renal function after cystectomy.
    Int J Urol. 2022;29:724.
    PubMed    


  72. MASTROIANNI R, Simone G
    Editorial Comment to Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
    Int J Urol. 2022;29:684.
    PubMed    


  73. SARI MOTLAGH R, Schuettfort VM, Mori K, Katayama S, et al
    Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
    Int J Urol. 2022;29:676-683.
    PubMed     Abstract available


  74. TOGASHI K, Hatakeyama S, Yoneyama T, Hamaya T, et al
    Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
    Int J Urol. 2022;29:733-739.
    PubMed     Abstract available


  75. KITA Y, Ito K, Sano T, Hashimoto K, et al
    Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
    Int J Urol. 2022;29:647-655.
    PubMed     Abstract available


    June 2022
  76. TANAKA T, Shindo T, Hashimoto K, Kobayashi K, et al
    Management of hydronephrosis after radical cystectomy and urinary diversion for bladder cancer: A single tertiary center experience.
    Int J Urol. 2022 Jun 30. doi: 10.1111/iju.14970.
    PubMed     Abstract available


  77. ARAI T, Sazuka T, Sato H, Imamura Y, et al
    Efficacy of photodynamic diagnosis-assisted transurethral resection of bladder tumor for T1 bladder cancer: Novel second transurethral resection initiatives utilizing photodynamic diagnosis.
    Int J Urol. 2022 Jun 20. doi: 10.1111/iju.14962.
    PubMed    


  78. NOHARA T
    Editorial Comment to Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.
    Int J Urol. 2022 Jun 19. doi: 10.1111/iju.14967.
    PubMed    


  79. TAOKA R, Sugimoto M
    Editorial Comment from Dr Taoka and Dr Sugimoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 Jun 11. doi: 10.1111/iju.14954.
    PubMed    


  80. MATSUMOTO K
    Editorial Comment from Dr Matsumoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 Jun 9. doi: 10.1111/iju.14955.
    PubMed    


  81. SHINDO T, Maehana T, Tanaka T, Hashimoto K, et al
    Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
    Int J Urol. 2022 Jun 2. doi: 10.1111/iju.14941.
    PubMed     Abstract available


  82. ZENNAMI K, Sumitomo M, Hasegawa K, Kozako M, et al
    Risk factors for postoperative ileus after robot-assisted radical cystectomy with intracorporeal urinary diversion.
    Int J Urol. 2022;29:553-558.
    PubMed     Abstract available


    May 2022
  83. LEE AY, Allen JC Jr, Teoh JY, Kang SH, et al
    Predicting perioperative outcomes of robot-assisted radical cystectomy: Data from the Asian Robot-Assisted Radical Cystectomy Consortium.
    Int J Urol. 2022 May 25. doi: 10.1111/iju.14937.
    PubMed     Abstract available


  84. WANG Z, So WZ, Loh KY, Lim YK, et al
    Predictive biomarkers of response to bacillus Calmette-Guerin immunotherapy and bacillus Calmette-Guerin failure for non-muscle invasive bladder cancer.
    Int J Urol. 2022 May 22. doi: 10.1111/iju.14921.
    PubMed     Abstract available


  85. MIYAKE M, Kikuchi E, Shinozaki K, Piao Y, et al
    Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 May 21. doi: 10.1111/iju.14933.
    PubMed     Abstract available


  86. HIRATA Y, Higuchi M, Osawa T, Hinotsu S, et al
    Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.
    Int J Urol. 2022 May 21. doi: 10.1111/iju.14936.
    PubMed     Abstract available


  87. FUJITA N, Hatakeyama S, Momota M, Narita T, et al
    Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guerin therapy.
    Int J Urol. 2022 May 16. doi: 10.1111/iju.14926.
    PubMed     Abstract available


  88. KANNO T, Kobori G, Ito K, Nakagawa H, et al
    Complications and their management following retroperitoneal lymph node dissection in conjunction with retroperitoneal laparoscopic radical nephroureterectomy.
    Int J Urol. 2022;29:455-461.
    PubMed     Abstract available


    April 2022
  89. TELLINI R, Mari A, Minervini A
    Editorial Comment from Dr Tellini et al. to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Apr 5. doi: 10.1111/iju.14895.
    PubMed    


  90. HAYAKAWA N, Kikuchi E
    Editorial Comment from Dr Hayakawa and Dr Kikuchi to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Apr 2. doi: 10.1111/iju.14888.
    PubMed    


  91. MIYAKE M
    Editorial Comment to Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.
    Int J Urol. 2022;29:364-365.
    PubMed    


  92. OZAKI K, Hatakeyama S, Hamaya T, Okita K, et al
    Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.
    Int J Urol. 2022;29:362-364.
    PubMed    


    March 2022
  93. NASELLI A, Pirola GM
    Editorial Comment from Dr Naselli and Dr Pirola to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Mar 31. doi: 10.1111/iju.14883.
    PubMed    


  94. KOBAYASHI K, Matsuyama H, Kawai T, Ikeda A, et al
    Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Mar 15. doi: 10.1111/iju.14854.
    PubMed     Abstract available


  95. URABE F, Matsuzaki J, Ito K, Takamori H, et al
    Serum microRNA as liquid biopsy biomarker for the prediction of oncological outcomes in patients with bladder cancer.
    Int J Urol. 2022 Mar 14. doi: 10.1111/iju.14858.
    PubMed     Abstract available


    February 2022
  96. IDE H
    Editorial Comment from Dr Ide to Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
    Int J Urol. 2022 Feb 25. doi: 10.1111/iju.14837.
    PubMed    


  97. KOGA F
    Editorial Comment to Predicting factor analysis of postoperative complications after robot-assisted radical cystectomy: Multicenter KORARC database study.
    Int J Urol. 2022 Feb 20. doi: 10.1111/iju.14832.
    PubMed    


  98. TAOKA R, Sugimoto M
    Editorial Comment to Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
    Int J Urol. 2022 Feb 15. doi: 10.1111/iju.14828.
    PubMed    


  99. LEOW JJ, Yong DZ, Chia PL
    Editorial Comment to Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.
    Int J Urol. 2022 Feb 10. doi: 10.1111/iju.14818.
    PubMed    


  100. KIM H, Jeong BC, Lee S, Ku JH, et al
    Predicting factor analysis of postoperative complications after robot-assisted radical cystectomy: Multicenter KORARC database study.
    Int J Urol. 2022 Feb 8. doi: 10.1111/iju.14815.
    PubMed     Abstract available


  101. YANG T, Liang H, Pei X, Zhang N, et al
    Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
    Int J Urol. 2022 Feb 5. doi: 10.1111/iju.14808.
    PubMed     Abstract available


  102. IQBAL U, Houenstein HA, Elsayed AS, Jing Z, et al
    Ileal conduit versus neobladder: A propensity score-matched analysis of the effect on renal function.
    Int J Urol. 2022;29:158-163.
    PubMed     Abstract available


  103. LIN MY, Niu SW, Li WM, Lee HL, et al
    Incidence and survival variations of upper tract urothelial cancer in Taiwan (2001-2010).
    Int J Urol. 2022;29:121-127.
    PubMed     Abstract available


    January 2022
  104. SHINDO T
    Editorial Comment from Dr Shindo to Prognostication in Japanese patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
    Int J Urol. 2022 Jan 4. doi: 10.1111/iju.14783.
    PubMed    


  105. GRAVESTOCK P, Coulthard N, Veeratterapillay R, Heer R, et al
    Response to Re: Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jan 1. doi: 10.1111/iju.14780.
    PubMed    


  106. CHEN CS, Li JR, Yang CK, Cheng CL, et al
    Significant predictors of contralateral upper tract recurrence after radical nephroureterectomy for upper tract urothelial carcinoma.
    Int J Urol. 2022;29:69-75.
    PubMed     Abstract available


  107. KIJIMA T
    Editorial Comment to Programmed cell death-ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma.
    Int J Urol. 2022;29:91.
    PubMed    


  108. TOMIYAMA E, Fujita K, Hashimoto M, Miyamoto H, et al
    Programmed cell death-ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma.
    Int J Urol. 2022;29:89-90.
    PubMed    


    December 2021
  109. HAYAKAWA N, Kikuchi E
    Editorial Comment to Incidence and location of perioperative deep vein thrombosis in patients with bladder cancer undergoing radical cystectomy.
    Int J Urol. 2021 Dec 28. doi: 10.1111/iju.14777.
    PubMed    


  110. TAGUCHI S
    Editorial Comment from Dr Taguchi to Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis.
    Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14768.
    PubMed    


  111. YUAN B, Cai L, Cao Q, Wu Q, et al
    Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis.
    Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14748.
    PubMed     Abstract available


  112. YOSHIDA S, Fujii Y
    Editorial Comment from Dr Yoshida and Dr Fujii to Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis.
    Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14771.
    PubMed    


  113. GOPALAKRISHNAN D, Elsayed AS, Hussein AA, Jing Z, et al
    Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.
    Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14749.
    PubMed     Abstract available


  114. SAZUKA T
    Editorial Comment to Prognostication in Japanese patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
    Int J Urol. 2021 Dec 15. doi: 10.1111/iju.14770.
    PubMed    


  115. NISHIMURA N, Miyake M, Iida K, Miyamoto T, et al
    Prognostication in Japanese patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
    Int J Urol. 2021 Dec 13. doi: 10.1111/iju.14759.
    PubMed     Abstract available


  116. KIKUCHI H, Abe T, Matsumoto R, Osawa T, et al
    Outcomes of bacillus Calmette-Guerin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era.
    Int J Urol. 2021 Dec 11. doi: 10.1111/iju.14761.
    PubMed     Abstract available


  117. YAMASHITA R, Nakamura M, Okayama Y, Kawase M, et al
    Incidence and location of perioperative deep vein thrombosis in patients with bladder cancer undergoing radical cystectomy.
    Int J Urol. 2021 Dec 9. doi: 10.1111/iju.14760.
    PubMed     Abstract available


  118. GOMEZ-OSPINA JC, Garcia-Perdomo HA
    Re: Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Dec 6. doi: 10.1111/iju.14764.
    PubMed    


  119. LONATI C, Moschini M
    Editorial Comment from Dr Lonati and Dr Moschini to Stage and cancer-specific mortality differ within specific Asian ethnic groups in upper tract urothelial carcinoma: North American population-based study.
    Int J Urol. 2021;28:1252-1253.
    PubMed    


  120. SHIOTA M
    Editorial Comment from Dr Shiota to Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study.
    Int J Urol. 2021;28:1253.
    PubMed    


  121. KATO M, Kobayashi T, Matsui Y, Ito K, et al
    Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.
    Int J Urol. 2021;28:1261-1267.
    PubMed     Abstract available


  122. COLLA RUVOLO C, Wurnschimmel C, Nocera L, Wenzel M, et al
    Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study.
    Int J Urol. 2021;28:1247-1252.
    PubMed     Abstract available


  123. SHIMIZU T, Hori S, Iemura Y, Tomioka A, et al
    Clinical significance of bladder deformity for intravesical recurrence after Bacillus Calmette-Guerin treatment.
    Int J Urol. 2021;28:1304-1305.
    PubMed    


    November 2021
  124. CHEN TJ, Chan TC, Li CF, Dilshan Sampath Dissanayaka D, et al
    High glycosyltransferase 8 domain containing two protein levels contribute to poor prognosis in urothelial carcinoma.
    Int J Urol. 2021;28:1178-1187.
    PubMed     Abstract available


    September 2021
  125. POLIKARPOV DM, Campbell DH, Zaslavsky AB, Lund ME, et al
    Glypican-1 as a target for fluorescence molecular imaging of bladder cancer.
    Int J Urol. 2021 Sep 8. doi: 10.1111/iju.14683.
    PubMed     Abstract available


  126. NASELLI A
    Editorial Comment to Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Sep 7. doi: 10.1111/iju.14687.
    PubMed    


  127. HARADA M, Tomisaki I, Minato A, Onishi R, et al
    Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
    Int J Urol. 2021;28:970-974.
    PubMed     Abstract available


  128. NARITA T, Hatakeyama S, Numakura K, Kobayashi M, et al
    Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
    Int J Urol. 2021;28:899-905.
    PubMed     Abstract available


    August 2021
  129. GRAVESTOCK P, Coulthard N, Veeratterapillay R, Heer R, et al
    Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Aug 27. doi: 10.1111/iju.14671.
    PubMed     Abstract available


  130. SHINDO T, Hashimoto K, Tanaka T, Taguchi K, et al
    Therapeutic options to reduce intravesical recurrence in newly diagnosed Ta high-grade bladder cancer according to risk stratification: A multicenter retrospective study.
    Int J Urol. 2021 Aug 3. doi: 10.1111/iju.14657.
    PubMed     Abstract available


  131. SETOGUCHI K, Saito K
    Editorial Comment from Dr Setoguchi and Dr Saito to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:821-822.
    PubMed    


  132. SHIGA M, Nagumo Y, Chihara I, Nitta S, et al
    Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:814-819.
    PubMed     Abstract available


  133. HATAKEYAMA S, Ohyama C
    Editorial Comment from Dr Hatakeyama and Dr Ohyama to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:820.
    PubMed    


  134. SAZUKA T
    Editorial Comment from Dr Sazuka to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:820-821.
    PubMed    


    July 2021
  135. SHIN T, Mimata H
    "Early-pull-out" technique for intracorporeal ileal conduit urinary diversion after robot-assisted radical cystectomy.
    Int J Urol. 2021;28:778-779.
    PubMed    


    May 2021
  136. FAN J, Wu K, Zhang N, Yang T, et al
    Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.
    Int J Urol. 2021 May 19. doi: 10.1111/iju.14592.
    PubMed     Abstract available


  137. MIYATA Y, Matsuo T, Sakai H
    Editorial Comment to Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.
    Int J Urol. 2021 May 19. doi: 10.1111/iju.14607.
    PubMed    


  138. KUROBE M
    Editorial Comment from Dr Kurobe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 May 3. doi: 10.1111/iju.14594.
    PubMed    


  139. IQBAL U, Durrani MM, Elsayed AS, Hussein AA, et al
    Functional outcomes after robot-assisted radical cystectomy: A review of literature.
    Int J Urol. 2021;28:493-501.
    PubMed     Abstract available


  140. FARAJ KS, Rose KM, Navaratnam AK, Abdul-Muhsin HM, et al
    Effect of intracorporeal urinary diversion on the incidence of benign ureteroenteric stricture after cystectomy.
    Int J Urol. 2021;28:593-597.
    PubMed     Abstract available


    April 2021
  141. LONATI C, Moschini M
    Editorial Comment from Dr Lonati and Dr Moschini to Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 22. doi: 10.1111/iju.14577.
    PubMed    


  142. URABE F
    Editorial Comment from Dr Urabe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14580.
    PubMed    


  143. SAITO R
    Editorial Comment from Dr Saito to Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14588.
    PubMed    


  144. KIJIMA T
    Editorial Comment from Dr Kijima to Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14581.
    PubMed    


  145. HAYASHI Y, Fujita K, Banno E, Eich ML, et al
    Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 Apr 15. doi: 10.1111/iju.14574.
    PubMed    


  146. YAMASHITA S, Iguchi T, Koike H, Wakamiya T, et al
    Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
    Int J Urol. 2021 Apr 5. doi: 10.1111/iju.14569.
    PubMed     Abstract available


    March 2021
  147. TEOH JY
    Editorial Comment to Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Mar 28. doi: 10.1111/iju.14563.
    PubMed    


  148. HATANO K, Nonomura N
    Editorial Comment from Dr Hatano and Dr Nonomura to Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 28. doi: 10.1111/iju.14559.
    PubMed    


  149. SETOGUCHI K, Saito K
    Editorial Comment from Dr Setoguchi and Dr Saito to Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 27. doi: 10.1111/iju.14561.
    PubMed    


  150. FUKUSHIMA H
    Editorial Comment from Dr Fukushima to Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 26. doi: 10.1111/iju.14558.
    PubMed    


  151. TAOKA R, Tsunemori H, Matsuoka Y, Kohashiguchi K, et al
    Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Mar 19. doi: 10.1111/iju.14548.
    PubMed     Abstract available


  152. HAYAKAWA N, Kikuchi E
    Editorial Comment to Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort.
    Int J Urol. 2021 Mar 18. doi: 10.1111/iju.14557.
    PubMed    


  153. MIYAMOTO T, Miyake M, Toyoshima Y, Fujii T, et al
    Clinical outcomes after intravesical bacillus Calmette-Guerin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
    Int J Urol. 2021 Mar 18. doi: 10.1111/iju.14545.
    PubMed     Abstract available


  154. TULLY KH, Reese SW, Cole AP, Noldus J, et al
    Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 14. doi: 10.1111/iju.14550.
    PubMed    


  155. HUANG H, Yan B, Hao H, Shang M, et al
    Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 13. doi: 10.1111/iju.14537.
    PubMed     Abstract available


  156. KANNO T
    Editorial Comment from Dr Kanno to Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 13. doi: 10.1111/iju.14551.
    PubMed    


  157. KUBOTA M, Kanno T, Inoue T, Yamasaki T, et al
    Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort.
    Int J Urol. 2021 Mar 7. doi: 10.1111/iju.14533.
    PubMed     Abstract available


    February 2021
  158. INOKUCHI J, Kuroiwa K, Nishiyama H, Kojima T, et al
    Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer.
    Int J Urol. 2021;28:208-214.
    PubMed     Abstract available


    November 2020
  159. NAKAGAWA T
    Lymph node dissection for bladder cancer: Current standards and the latest evidence.
    Int J Urol. 2020 Nov 3. doi: 10.1111/iju.14398.
    PubMed     Abstract available


  160. TANAKA H, Fujii Y
    Editorial Comment to Lymph node dissection for bladder cancer: Current standards and the latest evidence.
    Int J Urol. 2020 Nov 3. doi: 10.1111/iju.14419.
    PubMed    


  161. KOJIMA T
    Editorial Comment from Dr Kojima to Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma.
    Int J Urol. 2020;27:1031.
    PubMed    


  162. YOSHIDA T, Matsuda T
    Editorial Comment from Dr Yoshida and Dr Matsuda to Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma.
    Int J Urol. 2020;27:1030-1031.
    PubMed    


    September 2020
  163. TAOKA R, Matsuoka Y, Kohashiguchi K, Miura T, et al
    Impact of second transurethral resection on recurrence in patients with high-grade Ta bladder cancer.
    Int J Urol. 2020 Sep 28. doi: 10.1111/iju.14372.
    PubMed     Abstract available


  164. KHETRAPAL P
    Editorial Comment to Benefits of robotic cystectomy compared with open cystectomy in an Enhanced Recovery After Surgery program: A propensity-matched analysis.
    Int J Urol. 2020;27:788-789.
    PubMed    


    January 2020
  165. HERR H
    Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Guerin?
    Int J Urol. 2020;27:72-74.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.